Verrica Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
VRCA$3.52-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
BALANCE SHEETS
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $46,329 | $69,547 |
| Accounts receivable | 48 | 4,248 |
| Unbilled collaboration revenue | 29 | 168 |
| Inventory | 2,463 | 1,022 |
| Prepaid expenses and other current assets | 2,310 | 2,545 |
| Total current assets | 51,179 | 77,530 |
| Property and equipment, net | 589 | 1,052 |
| Operating lease right-of-use asset | 836 | 1,158 |
| Finance lease right-of-use asset | 1,154 | 1,405 |
| Other non-current assets | 376 | 452 |
| Total assets | $54,134 | $81,597 |
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,896 | $2,464 |
| Accrued expenses and other current liabilities | 13,511 | 13,860 |
| Current portion of long-term debt | 12,938 | — |
| Operating lease liability | 315 | 324 |
| Finance lease liability | 352 | 376 |
| Total current liabilities | 29,012 | 17,024 |
| Operating lease liability | 583 | 910 |
| Finance lease liability | 768 | 1,026 |
| Derivative liability | 2,648 | — |
| Long-term debt | 30,983 | 42,874 |
| Total liabilities | 63,994 | 61,834 |
| Commitments and Contingencies (Note 6) | ||
| Stockholders’ (deficit) equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 200,000,000 authorized; 91,885,137 shares issued and 91,779,993 shares outstanding as of December 31, 2024 and 42,518,697 shares issued and 42,413,553 shares outstanding as of December 31, 2023 | 9 | 4 |
| Treasury stock, at cost, 105,144 shares as of December 31, 2024 and December 31, 2023 | — | — |
| Additional paid-in capital | 297,158 | 250,207 |
| Accumulated deficit | (307,027) | (230,448) |
| Total stockholders’ (deficit) equity | (9,860) | 19,763 |
| Total liabilities and stockholders’ (deficit) equity | $54,134 | $81,597 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.